Horizon Discovery Group PLC - Gene editing company based in Cambridge - Signs set of commercial license agreements for CHOSOURCE gene editing platform with biopharmaceutical firm TrueBinding Inc. TrueBinding to use platform to help further its medication in immuno-oncology and other fields with "unmet medical need".
Current stock price: 103.50 pence
Year-to-date change: down 31%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.